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STAT3 Is Required for Flt3L-Dependent
Dendritic Cell Differentiation
The signals that control cell-fate decisions of a pro-
genitor commitment involve the interplay of both cyto-
kines and transcription factors. Flt3L (fms-like tyrosine
Yasmina Laouar,1,3 Thomas Welte,2,3
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kinase-3 ligand) is sufficient and indispensable to sup-Howard Hughes Medical Institute
port commitment and differentiation of hematopoieticYale University School of Medicine
progenitors to the DC lineage (McKenna, 2001). DirectNew Haven, Connecticut 06520
evidence came from extensive investigations of mice2 Department of Pathology
carrying a targeted disruption of the Flt3L gene (Mc-Yale University School of Medicine
Kenna et al., 2000), conditional overexpression of theNew Haven, Connecticut 06520
Flt3L gene (Manfra et al., 2003), and from in vivo models
of Flt3L administration (Maraskovsky et al., 1996; Pulen-
dran et al., 1997; Shurin et al., 1997). Flt3L gene deletionSummary
revealed abrogated DC development as indicated by
a 15-fold reduced DC compartment. Administration ofThe signals that control decisions of progenitor com-
Flt3L confirmed its direct effects on enhancing the DCmitment involve the interplay of both cytokines and
pool up to 80  106 DC in the spleen. Transgenic micetranscription factors. Flt3L has emerged as a potential
with conditional expression of murine Flt3L showed sus-regulator of dendritic cell (DC) development, but regu-
tained effects of continuous expression of Flt3L leadinglation of HSC commitment to the DC lineage remains
to an increased steady-state pool size of several DCpoorly understood. Our central finding is the identifi-
subsets in multiple lymphoid organs. Recently, the de-cation of STAT3 activation as a checkpoint of Flt3L-
finitive map of Flt3 receptor expression in the hemato-regulated DC development. Deletion of STAT3 caused
poietic hierarchy explained the potent effects of Flt3Lprofound deficiency in the DC compartment and abro-
on CLP and CMP developmental stages (Adolfsson etgated Flt3L effects on DC development. DC derivation
al., 2001; D’Amico and Wu, 2003; Karsunky et al., 2003;by Flt3L revealed a normal HSC pool, a 2- to 3-fold
Sitnicka et al., 2002). Further, transplantation of CMP oraccumulation of CLP/CMP, but absence of common
CLP with subsequent Flt3L injection caused increasedDC precursors as well as their DC progeny in STAT3-
progeny in DC of both CD8 and CD8 subsets (Kar-deficient mice. The formation of CMP and CLP repre-
sunky et al., 2003), thereby implying a role of Flt3L insents the first decisive lineage commitment step, and
the common DC pathway. How this cytokine regulatesin this regard we provide evidence that commitments
commitments to the DC lineage remains, however,of CLP/CMP to the DC lineage strictly depend on the
poorly understood.interplay of both Flt3L and STAT3 activation.
Flt3L acts through the Flt3 receptor, also termed Flk-2
(Matthews et al., 1991) and STK-1 (Small et al., 1994).Introduction
The Flt3 receptor belongs to the type III receptor tyrosine
kinase family that includes receptors for SLF, PDGF,The differentiation of hematopoietic stem cells (HSC)
and M-CSF (Rosnet and Birnbaum, 1993). This cytokinefollows an orchestrated program of cell differentiation
receptor family acts through different signaling path-that becomes progressively restricted along distinct de-
ways, but all include the activation of STAT transcriptionvelopmental lineages. The initial differentiation of HSC
factors. The presence of seven STAT family membersresults in separation into distinct lymphoid and myeloid
differentially activated by distinct receptors, however,
differentiation pathways, reflected in the generation of
adds potential for considerable specificity (O’Shea et al.,
common lymphoid (CLP) and myeloid (CMP) progenitors
2002). Unlike other STATs, ablation of STAT3 produced
(Akashi et al., 2000; Kondo et al., 1997) that subsequently early embryonic lethality (Takeda et al., 1997), sug-
lead to the production of distinct lineages. For the deri- gesting that STAT3 might be generally required for de-
vation of dendritic cells (DC), the concept of dichoto- velopmental processes. The production of tissue-spe-
mous lymphoid versus myeloid lineages was originally cific knockouts using Cre-lox technology (Akira, 2000)
proposed based on the existence of both myeloid revealed a key role of STAT3 in the regulation of hemato-
(CD8)- and lymphoid (CD8)-derived DC (Anjuere et poietic-derived cell homeostasis including a negative
al., 1999; Ardavin et al., 1993; Vremec et al., 1992; Wu feedback loop necessary for controlling macrophage
et al., 1996). This concept was challenged subsequently (Welte et al., 2003) and neutrophil (Lee et al., 2002) num-
by several reports, demonstrating that both CD8 and bers. However, despite extensive studies on the devel-
CD8 DC can be generated from either CLP or CMP opment of myeloid cells in response to hematopoietic
(Anjuere et al., 2000; Manz et al., 2001; Martin et al., cytokines, involvement of STAT3 activation in DC devel-
2000; Traver et al., 2000). The recently characterized opment has never been investigated.
DC-committed precursor, common to all DC subsets, Here, we provide direct evidence that STAT3 is indis-
finally provided the basis for integrating a unified model pensable in Flt3L-regulated DC development. Ablation
of DC diversity (del Hoyo et al., 2002). of STAT3 in hematopoietic-derived cells led to a con-
tracted DC compartment and abolished the effects of
Flt3L on DC generation. Studies on DC derivation showed*Correspondence: xin-yuan.fu@yale.edu
3These authors contributed equally to this work. that the requirement of STAT3 in the Flt3L pathway is
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Figure 1. Deletion of STAT3 Induced Profound Defects in the DC Compartment
(A) Mice carrying a conditional deletion of the STAT3 gene in hematopoietic cells were analyzed at 3–4 weeks of age. (a and b) Splenocytes
were stained with anti-CD11c antibody, and the frequency of DC per spleen was determined as indicated in the designated gates. (c and d)
Mice were treated (i.p.) with LPS (5 mg/kg body weight) for 6 hr to allow recruitment of DC from different organs into the spleen. Results are
representative of n  10 (a and b) and n  4 (c and d).
(B) Total cell numbers of freshly isolated thymocytes (TCR), splenic B cells (B220), splenic DC (CD11c), and splenic macrophages
(CD11b) are represented from STAT3/ (black) or STAT3/ (gray) mice.
(C) Deletion of STAT3 was analyzed by Western blotting in sorted thymocytes, B cells, and macrophages. Since DC frequency was limiting
in STAT3/ mice, deletion of STAT3 was analyzed using in vitro BM-derived DC (see Figure 5 for details), and brain was used as control of
STAT3 expression in nonhematopoietic-derived cells. Protein levels of STAT3 are shown as indicated. Results are representative of n  10
with (*) significant difference (p  .05) from control STAT3/ mice.
stage specific and is restricted to the transitions from STAT3/ versus STAT3/, respectively, n  10, p 
0.05; Figure 1B). Mature T and B cells showed noCMP/CLP to common DC precursors. Thus, this report
shows a critical mechanism by which the differentiation changes despite the efficient deletion of STAT3 protein
(Figure 1C), supporting the specific role of STAT3 in theof HSC into DC is regulated through the Flt3L-STAT3
pathway. maintenance of DC homeostasis.
To further ascertain the causes of atrophy in the DC
pool of the STAT3-deficient mice, migration of DC into
Results the spleen was investigated. We found that treatment
of mice with LPS, known to provoke the recruitment of
STAT3 Is a Positive Regulator for DC Homeostasis DC from different organs into the spleen (Foti et al.,
Studies of mice lacking expression of STAT3 in hemato- 1999), confirmed defects of the DC compartment in
poietic progenitors originally revealed the role of STAT3 STAT3-deficient mice (Figure 1A). While LPS administra-
as a negative regulator of myeloid-derived lineages in- tion in control mice recruited 21% DC into the spleen,
cluding macrophages (Welte et al., 2003) and neutro- only2.5% DC were recovered in STAT3-deficient mice
phils (Lee et al., 2002). In contrast to previous reports, (n 4). The frequency of total DC recruited to the spleen
we found that STAT3 is instead a positive regulator for is at least 10-fold lower in STAT3-deficient mice, sug-
normal homeostasis of the DC pool (Figure 1). gesting defects in DC development in the absence of
Murine DC represent4%–6% of total cells in periph- STAT3.
eral lymphoid organs. To examine the outcome of STAT3
deletion on DC homeostasis, cells were isolated from
STAT3-deficient mice (Welte et al., 2003), and then their STAT3 Is Indispensable for Flt3L-Regulated
DC Developmentfrequency and numbers were determined by FACS anal-
ysis (Figures 1A and 1B). We found that DC homeostasis In vivo DC development is dependent on the Flt3L path-
way (McKenna, 2001), yet transcription factors essentialwas dramatically impaired in STAT3-deficient mice as
indicated by the severely reduced DC compartment in for Flt3L-regulated DC differentiation have never been
determined. To this aim, we administered Flt3L (Mara-the spleen (0.41% 0.1 versus 3.57% 1.2 in STAT3/
versus STAT3/ mice, respectively, n  10, p  .05; skovsky et al., 1996) to monitor in vivo newly formed
DC in the absence of STAT3. If STAT3 activation is notFigure 1A). While STAT3 deletion was originally found
responsible for macrophage accumulation, the absence required in DC differentiation mediated by Flt3L, we
assumed that administration of Flt3L would overcomeof STAT3 induced, in addition, a profound reduction of
the DC pool (3.8  106  0.3 versus 0.5  106  0.1 in the deficit of the DC pool caused by STAT3 deletion.
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Table 1. Effects of Flt3L Administration on the Relative Numbers of STAT3-Deficient Cells
Untreated Mice Flt3L-Treated Mice
Cell Subsets STAT3/ STAT3/ STAT3/ STAT3/
T lymphocytes 21  3.2 26  5.8 34  8.7 31  11
B lymphocytes 60  9.3 55  11 80  13 71  8.1
NK cells 3.2  0.9 4.0  1.3 6.8  2.3 4.9  1.5
Macrophages 4.8  1.2 23  9.5 15  3.6 28  7.6
Dendritic cells 3.3  1.8 0.4  0.1 92  15.8 0.8  0.2
STAT3/ and STAT3/ mice were injected daily (i.p.) with 10 	g Flt3L for 9 days as previously described. Cells recovered from spleen were
counted and then analyzed by flow cytometry using antigen-specific antibodies. Results are presented as the absolute number (106) of
different cell subsets isolated from untreated and Flt3L-treated mice (n  5).
However, Flt3L failed to restore a normal DC compart- al., 1999). Both CD8 and CD8 DC subsets can be
expanded by Flt3L up to a total of 50  106 cells perment in STAT3-deficient mice (Table 1). While Flt3L gen-
erated more than 90 million DC in control mice, less spleen, respectively (Maraskovsky et al., 1996; Pulen-
dran et al., 1997; Shurin et al., 1997). The relative propor-than one million DC were recovered in STAT3-deficient
mice (92 106 15.8 versus 0.8 106 0.2 in STAT3/ tions of CD8 versus CD8DC were next investigated
in Flt3L-treated STAT3-deficient mice (Figures 3A–3C).versus STAT3/ mice, n  5, p  .05). Other cell types
such as NK cells and T and B lymphocytes are known We found a complete lack of CD8 DC in STAT3-defi-
cient mice while a substantial population was generatedto respond to Flt3L by significant expansion (Brasel et
al., 1996), yet they showed no differences in their re- in lymphoid organs of control mice reaching maximal
DC accumulation in the spleen (Figures 3B and 3C).sponse to Flt3L regardless of whether STAT3 is absent
or present. Such a response was not observed in STAT3- The generation of CD8 DC was also abrogated in the
absence of STAT3 as shown by determination of celldeficient macrophages given that this cell compartment
was already increased in untreated STAT3/ mice. To frequency (Figures 3B and 3C) and confirmed by quanti-
tating cell numbers (0.8  106  0.2 versus 43  106 further ascertain Tie2-Cre activity in Flt3L-derived cells,
Tie2-Cre mice expressing a GFP reporter of Cre activity 13.8 cells from STAT3/ versus control STAT3/ mice,
n  8, p  .05). Consequently, the expression of PU.1were treated with Flt3L and different lymphoid organs
were subsequently analyzed for GFP expression (Figure and RelB, known to be important transcription factors
in the development of CD8 DC (Guerriero et al., 2000;2). FACS analysis demonstrated efficient GFP expres-
sion—by inference efficient STAT3 gene deletion—in Wu et al., 1998), was investigated. Because STATs can
interact with PU.1 (O’Shea et al., 2002), the possibilityFlt3L-derived DC, macrophages, and lymphocytes iso-
lated from BM, lymph nodes, spleen, and thymus. that STAT3 deletion may affect this factor leading to
abrogated CD8 DC development was considered.Differentiated DC are subdivided into two major cell
populations according to CD8 expression (Anjuere et However, Western blot analysis revealed normal expres-
Figure 2. Efficient Gene Deletion in Flt3L-
Derived Cells
Tie2-Cre activity was assessed in Flt3L-
derived cells using Tie2-Cre mice expressing
GFP reporter. Mice were treated (i.p.) with
Flt3L (10 	g) for 9 consecutive days, and GFP
expression was determined in BM, lymph
nodes, spleen, and thymus. FACS analysis
using anti-TCR (for T cells), anti-B220 (for
B cells), anti-CD11c (for DC), or anti-CD11b
(for macrophages) showed 
80%  15 of
GFP expression in all BM-derived cell types
(n  6).
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Figure 3. Sustained Defects of DC Development in STAT3-Deficient Mice after Flt3L Treatment
Mice were treated (i.p.) with Flt3L (10 	g) for 9 consecutive days. Subsequently, cells were recovered from spleen (a), mesenteric (b), or
peripheral (c) lymph nodes and analyzed by FACS staining using antibodies specific to CD11c, CD8, and IE/IA molecules. As designated by
specific gates, FACS plots represent the frequency of total CD11c DC (A), CD11c CD8 DC subset (B), and mature CD11c IE/IAhigh DC
(C). Results (A–C) are representative of n  8 mice. (D) Mice were treated (i.p.) for 4 days with 5-fluorouracil (150 mg/kg body weight) to
eliminate committed progenitors from the BM. Subsequently, primitive progenitors were isolated from STAT3/ (lanes 1 and 2) or STAT3/
(lanes 3 and 4) and analyzed by Western blot for expression of PU-1 and RelB factors. Proteins levels of STAT3 and -actin are shown as
indicated, and results are shown from two individual mice.
sion level of both PU.1 and RelB in STAT3-deficient BM The common DC precursor is presumably located
progenitors (Figure 3D). Thus, data directly demonstrate downstream of CMP and CLP, both of which represent
that Flt3L-dependent dendropoiesis requires STAT3 ac- the first lineage commitment step by HSC. HSC as de-
tivation. fined by Lin c-kit Sca-1 cells contains most long-
term multilineage reconstituting activity in murine BM
(Ikuta and Weissman, 1992; Okada et al., 1991) as wellSTAT3 Is Required during Transitions from CLP/CMP
as Flt3-expressing cells (Adolfsson et al., 2001; D’Amicoto Common DC Precursor
and Wu, 2003; Karsunky et al., 2003; Sitnicka et al.,In an attempt to trace the requirement of STAT3 activa-
2002). To determine the pool size of HSC in STAT3-tion during dendropoiesis, we first investigated out-
deficient BM, mice were treated with 5-fluorouracilcomes of STAT3 deletion on common DC precursor cells
(5-FU), and the frequency of c-kit Sca-1 cells was(Figure 4). Common DC precursors have been defined
determined 4 days later as previously described (Randallto be the immediate DC progenitors that lead to full
and Weissman, 1997). In vivo treatment with 5-FU isreconstitution of all DC including both CD8 and
commonly used to eliminate committed progenitors,CD8 DC subsets without other myeloid or lymphoid
and thereby only primitive hematopoietic progenitorsdifferentiation potential (del Hoyo et al., 2002). Surpris-
remain in the BM. We found that deletion of STAT3 didingly, analysis of the BM compartment revealed potent
not affect the frequency of the c-kit Sca-1 primitiveeffects of Flt3L in STAT3/ but not in STAT3/ mice
progenitors (Figure 4B). Analysis of Flt3 receptor expres-in the generation of CD11c CD8 IE/IA B220
sion showed no difference between control and STAT3-CD11b c-kit IL-7R common DC precursor cells
deficient cells (data not shown), and administration of(25  7.2% versus 2  0.6% in STAT3/ versus
Flt3L had no differential effect on the pool size of thisSTAT3/ mice, n  8, p  .05; Figure 4A). Although
population regardless of whether STAT3 was present ormuch evidence previously attributed the role of Flt3L in
absent (Figure 4C). Consistent with the normal HSC poolDC development to its ability to target the progenitor
that was reported in Flt3L-deficient mice (Sitnicka et al.,pool, our data directly demonstrate an effect of Flt3L
2002), our results showed an unchanged HSC compart-on the immediate DC precursors. Data from STAT3-
ment in STAT3-deficient mice as well.deficient mice indicated, however, that regulation by
Nevertheless, transition from HSC to CLP is depen-STAT3 is required prior to the transition into the common
DC precursor stage. dent on Flt3L. While CMP and HSC were unaffected,
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Figure 4. Outcomes of STAT3 Deletion on Early and Immediate DC Progenitors
(A) Mice were treated (i.p.) with Flt3L (10 	g) for 9 consecutive days, and cells recovered from BM were analyzed by FACS staining using
anti-CD11c, anti-CD8, and anti-IE/IA antibodies. Numbers in designated gates indicate the frequency of CD11c, CD11c CD8, and CD11c
IE/IA cells. Up to 90% of CD11c cells generated by Flt3L treatment in the BM were negative for both CD8 and MHC class II markers
(n  8). Gated CD11c CD8 IE/IA showed positive expression of B220 (blue dots) and CD11b (data not shown) markers but negative
expression of IL-7R (red dots) and c-kit (data not shown) and define, therefore, the phenotypic characterization of immediate DC progenitors.
(B)–(E) show the effect of STAT3 on early DC progenitors.
(B) Primitive progenitors were first enriched by 5-fluorouracil treatment, then analyzed by FACS staining using antibodies specific to c-kit and
Sca-1. Frequencies of c-kitSca-1 primitive progenitors from STAT3/ or STAT3/ mice are shown in designated gates. Western blot
analysis confirmed efficient deletion of STAT3 protein in the total primitive precursor population (b) or in the sorted primitive c-kit Sca-1
progenitor cell subset (a).
(C–E) Mice were treated with Flt3L as described above. BM cells were recovered and stained with a cocktail of lineage (Lin) antibodies (B220,
Gr-1, CD11b, CD4, CD8, TER-119) together with antibodies against Sca-1, c-kit, CD34, and IL-7R. (C) Frequency of cells within Lin Sca1
c-kit HSC pool. (D) Frequency of CLP as defined by IL-7R expression on gated Lin c-kit Sca1 cells. (E) Frequency of CMP and GMP
as defined by CD34-expressing cells on gated Lin IL-7R Sca-1 cells. Results are representative of three independent experiments.
the frequency of CLP was reduced 10-fold in Flt3L- c-kit Sca1 progenitors while CMP fall into the CD34-
expressing cell compartment within Lin IL-7R Sca1deficient mice (Sitnicka et al., 2002). We next investi-
gated whether STAT3 deletion may result in a similar c-kit progenitors. A detailed FACS analysis revealed a
significant abundance of CLP and CMP caused by Flt3Loutcome by examining the relative frequency of CLP and
CMP generated by Flt3L. According to several studies in STAT3-deficient mice (Figures 4D and 4E). As indi-
cated by an overlay of IL-7R expression within the Lin(Adolfsson et al., 2001; D’Amico and Wu, 2003; Karsunky
et al., 2003; Sitnicka et al., 2002), CLP comprise the c-kitSca1 compartment and CD34 expression among
Lin IL-7R Sca1 c-kit progenitors, STAT3-deficientpopulation of IL-7R-expressing cells among Lin
Immunity
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progenitors displayed a 2- to 3-fold accumulation of CSF pathway as previously reported (Al-Shami et al.,
1998; Feldman et al., 1997; Lehtonen et al., 2002; WelteCLP and CMP when compared to their respective con-
trols. The fact that Flt3L caused (1) an unaffected HSC et al., 1997). In contrast, we found that Flt3L specifically
requires STAT3 activation.pool and (2) accumulation of CLP/CMP while causing
(3) atrophy of the common DC precursor compartment
in STAT3-deficient mice conclusively defines the re- Discussion
quirement of STAT3 in Flt3L pathway during the transi-
tions from CLP/CMP to common DC precursors. The primary role of cytokines in hematopoiesis is the
regulation of cell fate decisions of progenitor cells. Our
central finding is the identification of STAT3 activation asSTAT3 Is Indispensable in Flt3L- but Not
in GM-CSF-Dependent DC Differentiation In Vitro a checkpoint event in Flt3L-regulated DC development.
Deletion of STAT3 in hematopoietic-derived cells causedThe effects of exogenous cytokines on DC differentia-
tion from hematopoietic precursors has been exten- a profound deficiency in the DC compartment, and ad-
ministration of Flt3L remained without effects on DCsively examined using in vitro systems. DC progeny gen-
erated in vitro by GM-CSF or Flt3L are now well defined: development. Phenotypic characterization of hemato-
poietic progenitors at defined developmental stagesDC derived from GM-CSF-supplemented cultures ex-
press cell surface antigens typically associated with demonstrated that commitment to common DC precur-
sors was dependent on STAT3 activation.CD11c CD11b “myeloid” DC (Inaba et al., 1992) while
DC derived from Flt3L-supplemented cultures exhibit A major function of Flt3L had originally emerged as a
potential regulator of the HSC pool by promoting transi-characteristics typically associated with plasmacytoid
CD11c CD11b DC (Brawand et al., 2002; Gilliet et al., tion from HSC into CLP (Borge et al., 1999; Ogawa et
al., 1998; Sitnicka et al., 2002; Williams et al., 1999),2002). We used this approach and directly compared
the activity of Flt3L versus GM-CSF on DC differentiation thereby controlling the development of several lymphoid-
derived cells. Nevertheless, we found that in the ab-in the absence of STAT3.
First, we determined whether STAT3 activation was sence of STAT3, while Flt3L was able to effect NK cells
and T and B lymphocyte development with no differenceindispensable in GM-CSF-mediated DC differentiation.
To this aim, BM cells were cultured with GM-CSF, and from control cells, it remained without affect on the DC
pool. We found that development of STAT3-deficientthe frequency of derived-DC was determined by FACS
analysis (Figure 5A). Alternatively, BM-derived DC were progenitors induced by Flt3L results in a normal HSC
pool, in a 2- to 3-fold accumulation of CLP and CMPrecovered and stimulated with LPS to assess levels of
DC maturation. We found that STAT3-deficient precur- but in the absence of common DC precursors as well
as their differentiated DC progeny. Although CMP ac-sors can differentiate normally into CD11c CD11b DC
in response to GM-CSF (33%  11 and 44%  9 in count for 0.2% and CLP for only 0.02% of whole BM,
transplantation approaches revealed an equal contribu-control and STAT3/ cells, respectively, n  6) and
subsequently mature in response to LPS (MHC class II tion of CMP and CLP to the production of DC (Manz et
al., 2001). This developmental potential to become a DCand CD80 upregulation) with no difference from control
cells. In contrast, we found that Flt3L failed to generate is efficiently maintained by progenitors downstream of
the CLP and CMP stages as they become progressivelythe CD11c CD11b DC subset in STAT3-deficient cul-
tures (Figure 5B). We analyzed the progeny of BM pre- restricted to the common DC precursors (del Hoyo et
al., 2002). Recently, gene expression studies have corre-cursors induced by Flt3L over a 15 day period and con-
firmed that plasmacytoid DC could not be generated lated transitions from HSC toward committed progeni-
tors with the downregulation of large numbers of HSC-from STAT3-deficient precursors (15% versus2% in
control versus STAT3/ cultures). associated genes and progressive upregulation of a
limited numbers of lineage-specific genes (Terskikh etTo confirm directly that STAT3 activation is indispens-
able in the Flt3L but not in the GM-CSF pathway, we al., 2003). In this context, data from Flt3 expression
in the hematopoietic hierarchy provided evidence thatcompared the activation pattern of STAT factors in re-
sponse to both cytokines. Committed progenitors were expression of Flt3 receptor is a lineage-specific event
(D’Amico and Wu, 2003; Karsunky et al., 2003). Indeed,first eliminated from BM by in vivo treatment with 5-FU,
and then primitive progenitors were stimulated with the frequency of the expression of Flt3 is greater in CLP
(60%–70%) and CMP (50%–65%) than in HSC (Chris-Flt3L or GM-CSF (Figure 5C). While GM-CSF induced
simultaneously the phosphorylation of STAT1, STAT3, tensen and Weissman, 2001), maintained at low levels
in GMP but is downregulated and lost once definitiveand STAT5, our results demonstrated that STAT3 was
activated by Flt3L. Phosphorylation of the two isoforms B cell, T cell, and megakaryocyte/erythrocyte lineage
commitment occur. By contrast, definitive commitmentof STAT3 ( and ) was detectable 15 min after stimula-
tion with different doses of Flt3L (Figure 5D); neither to the DC lineage as revealed by the generation of com-
mon DC precursors is associated with conserved ex-STAT1 nor STAT5 was phosphorylated by Flt3L (Figure
5C). Finally, we determined whether the absence of pression of Flt3, indicating that conserved DC genera-
tive capacity and maintenance of Flt3 expressionSTAT3 activation may affect phosphorylation of other
STATs taking into consideration potential interactions converge at similar differentiation checkpoints. Consis-
tent with this, our results demonstrated potent effectsof STAT3 with STAT1 (Sadowski et al., 1993). Both
STAT1 and STAT5 were activated normally in response of Flt3L on CD11c CD8 IE/IA B220 CD11b c-kit
IL-7R common DC precursor cells. Nevertheless, reg-to GM-CSF (Figure 5E), suggesting that phosphorylation
of STAT1 and/or STAT5 might be sufficient in the GM- ulation by STAT3 appears to occur prior to the transition
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Figure 5. Normal Differentiation of STAT3-Deficient BM Precursors in Response to GM-CSF but Not to Flt3L In Vitro
(A) BM cells were isolated from STAT3/ or STAT3/ mice and cultured in GM-CSF (20 ng/ml) for 6 days. Nonadherent cells were recovered
and analyzed by FACS staining to determine the frequency of “myeloid” DC as defined by CD11c CD11b phenotype. Subsequently, BM-
derived DC were treated with LPS (18 hr, 10 ng/ml) and then analyzed for the expression of MHC class II marker as well as CD80 costimulatory
marker. Numbers shown denote the percentage of CD11c CD11b DC, and results are representative of four independent experiments.
(B) BM cells were isolated from STAT3/ or STAT3/ mice and cultured in Flt3L (100 ng/ml) for 15 days. Nonadherent cells were recovered
and analyzed by FACS staining to determine the frequency of plasmacytoid DC as defined by CD11c CD11b phenotype. Numbers shown
denote the percentage of CD11c CD11b and CD11c CD11b DC, and results are representative of two independent experiments.
(C and D) BM primitive progenitors were first enriched by 5-fluorouracil treatment, then stimulated for 15 min in the presence of Flt3L (lane
2) or GM-CSF (lane 3). Alternatively, BM primitive progenitor were stimulated with different doses of Flt3L: 1.35 	g/ml (lane 2, 5, and 7) or
0.25 	g/ml (lane 3) for 15 min (lanes 1–5) or 60 min (lane 6 and 7). Activation of different STAT factors was determined by Western blot using
antibodies specific to phospho-Y701-STAT1, phospho-Y705-STAT3  and , and phospho-Y694-STAT5. Protein levels of different STAT
factors and -actin are shown as indicated.
(E) Pattern of STAT activation was investigated in response to GM-CSF using BM-derived DC. Cells were first extensively washed and starved
for 4 hr in medium without GM-CSF, then stimulated for 15 min in the presence of GM-CSF. Proteins and phosphorylation levels of different
STATs are shown as indicated. Samples from STAT3-deficent mice are indicated by KO, and the results are representative of three indepen-
dent experiments.
into the common DC precursor stage. The formation tion of end-stage maturation from CD8 into CD8
subset (del Hoyo et al., 2002; Merad et al., 2000; Naikof CMP and CLP represent the first decisive lineage
commitment step before the generation of several dis- et al., 2003). This concept is, however, being revised
since both RelB and PU.1 are expressed in CD8 andtinct lineages, and in this regard we here provide evi-
dence that STAT3 is a nonredundant regulator of CLP/ CD8 DC as well as in CLP and CMP (Manz et al., 2001;
Traver et al., 2000). Most interesting is the induction ofCMP commitments to DC lineage.
The observation that Flt3L failed to promote the gener- PU.1 by Flt3L (Mizuki et al., 2003) and interaction of
PU.1 with STAT3 (Panopoulos et al., 2002). Accordingly,ation of both CD8 and CD8 DC subsets in STAT3-
deficient mice establishes a requirement for STAT3 acti- one hypothesis to explain the effect of STAT3 was that
STAT3 deletion might affect PU.1 expression leading tovation in the common pathway of DC development. To
date, three other transcription factors, Ikaros, RelB, and abrogated development of DC. But analysis of protein
expression confirmed normal levels of RelB and PU.1PU.1, have been shown to affect DC development, but
instead all showed a selective requirement in the CD8 expression in STAT3-deficient precursors with no differ-
ence from control cells. Still, we can not exclude inter-DC subset. One interpretation attributed the selective
absence of CD8 DC in RelB- and PU.1-deficient mice play of Flt3L with PU.1 and STAT3 controlling different
steps of DC development. In this regard, whether the(Guerriero et al., 2000; Wu et al., 1998) to a rapid transi-
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absence of CD8 DC in PU.1-deficient mice may be isoforms contribute to control DC development remains
explained by the involvement of the Flt3L-PU.1 pathway to be investigated. The finding that the interplay of cyto-
in modulating divergence of common DC precursors kine and transcription factor can instructively drive lin-
into both CD8 and CD8 DC subsets remains to be eage commitment will allow elucidation of the molecular
investigated. The point of particular interest here is that mechanisms that regulate hematopoietic cell differenti-
the Flt3L-STAT3 pathway defines a specific checkpoint ation.
in the common DC differentiation.
We further extended these findings and investigated Experimental Procedures
the effects of Flt3L on DC development in the absence
Miceof the potential influence of the hyperinflammatory mi-
Mice homozygous for a STAT3 allele with two loxP sites in intronscroenvironment of STAT3-deficient mice (Welte et al.,
17 and 20 (F allele) were on a mixed 129/C57B6 background. To2003). Flt3L is a potent inducer of CD11c CD11b CD8 generate conditional STAT3-deficient mice, homozygous STAT3
plasmacytoid DC in vitro (Brawand et al., 2002; Gilliet floxed mice were bred with Tie2-Cre. This strain had been back-
et al., 2002), and our finding that it failed to generate this crossed to C57B6 for at least nine generations. The genotype of
the offspring was determined by PCR with the following primers.cell subset from STAT3/ precursors directly emphasizes
5-ATTGGAACCTGGGACCAAGTGG-3 and 5-ACATGTACTTACAGthe role of the Flt3L-STAT3 pathway in the development
GGTGTGTGC-3 yield a 490 bp product with the wild-type STAT3of DC in vivo. The characterization of the physiological
allele and a 520 bp product with the F allele. CreF 5-CGATGCAACtolerogenic DC showed recently that the plasmacytoid
GAGTGATGAGG -3 and CreB 5-CGCATAACCAGTGAAACAGC-3
CD11c CD11b DC are endowed with high tolerogenic yield a 300 bp PCR product with the Tie2-Cre transgene. When
potential capable of inducing T-anergic and T-regulatory indicated, GFP-reporter mice crossed with Tie2-Cre mice (Novak et
cells and thereby of controlling peripheral T cell toler- al., 2000) have been used. Age- and sex-matched STAT3/ and
STAT3/ mice were used. STAT3/ mice from different agesance (Martin et al., 2002). Plasmacytoid DC are thus an
showed impaired DC development, and the results presented in thisimportant physiological subset of tolerogenic DC, and
study are from 3- to 4-week-old mice.in this regard the absence of such a DC subset, both in
Flt3L-treated STAT3-deficient mice and in Flt3L-supple-
Mice Treatmentmented STAT3-deficient BM cultures, might play a role
Flt3 ligand: Mice were treated (i.p.) for 9 consecutive days with 10in the development of hyperinflammatory responses ob-
	g Flt3L (Immunex) plus 1 	g mouse serum albumin as previously
served in STAT3/ mice. described (Maraskovsky et al., 1996). Subsequently, mice were sac-
The fact that STAT3-deficient BM precursors were rificed, and different organs (thymus, spleen, bone marrow, periph-
eral and mesenteric lymph nodes) were isolated.able to differentiate normally in response to GM-CSF is
LPS: Mice were treated (i.p.) for 6 hr with E. coli LPS (5 mg/kgindicative of two important issues. (1) The potential of
body weight) as previously described (Foti et al., 1999). Subse-myelopoiesis if not hematopoiesis of STAT3-deficient
quently, mice were sacrificed and spleen was harvested.BM is conserved, and (2) the involvement of STAT3 acti-
5-fluorouracil: Mice were treated (i.p.) for 4 days with 5-FU (150
vation is dispensable in GM-CSF-dependent DC differ- mg/kg body weight) as previously described (Randall and Weiss-
entiation. Furthermore, the pattern of STATs factor acti- man, 1997). Subsequently, mice were sacrificed, and bone marrow
vation induced by Flt3L versus GM-CSF provided direct cells were obtained.
evidence for the involvement of, but not a nonredundant
requirement for, STAT3 in the GM-CSF pathway. Specifi- FACS Analysis
Single-cell suspensions were treated with Fc-receptor block (2-4G2)cally, our results showed phosphorylation of STAT1,
and then stained with monoclonal antibodies conjugated to FITC,STAT3, and STAT5 by GM-CSF stimulation, and previ-
PE, PerCP, or APC. Biotinylated antibodies were revealed usingous studies indicating a specific role of STAT5 activation
conjugated streptavidin. We used the following antibodies (Phar-in the GM-CSF pathway are in agreement with these
mingen): anti-CD11c, anti-CD11b, anti-B220, anti-TCR, anti-
data (Al-Shami et al., 1998; Feldman et al., 1997; Lehto- NK1.1, anti-CD8, anti-IE/IA, anti-CD80, anti-c-Kit, anti-Sca1, anti-
nen et al., 2002; Welte et al., 1997). Importantly, our IL-7R, anti-CD34, anti-CD4, anti-CD8, anti-GR1, and anti-TER119.
results directly demonstrate that Flt3L specifically acti- Analysis and cell sorting were performed using FACSCalibur and
FACSVantage, respectively.vates STAT3. Nevertheless, our finding does not exclude
the possibility that Flt3L can activate other STAT pro-
In Vitro Culturesteins. Previous work by Zhang et al. (2000) provided
Dendritic cells: Single-cell suspensions of bone marrow were de-evidence of STAT5 activation by Flt3L in a murine IL-3-
pleted of red blood cells by RBC lysis buffer treatment. B220,dependent hematopoietic cell line Baf3/Flt3, suggesting
CD4, and CD8 cells were removed through complement mediatedthat signaling by Flt3L may be mediated through differ-
cell lysis. Dendritic cells were generated by culturing depleted-BM
ent STATs depending on the cell type and/or cell differ- cells in RPMI-1640 supplemented with 10% FCS, 60	g/ml penicillin,
entiation. With this regard, our finding that STAT3 dele- 100	g/ml streptomycin, and 20 ng/ml rGM-CSF or 100 ng/ml murine
tion did not affect Flt3L actions on other cell types such Flt3L (R&D Systems). GM-CSF- and Flt3L-supplemented cultures
were analyzed after 6 and 15 days, respectively. When indicated,as NK cells and T and B lymphocytes worked in favor
BM-derived dendritic cells were treated with LPS (10 ng/ml) for 18of this hypothesis.
hr and then analyzed by FACS.In conclusion, this report shows a critical mechanism
by which the differentiation of HSC into DC is regulated
Western Blotthrough the Flt3L-STAT3 pathway. Due to alternative
Blots were prepared on PVDF membranes and incubated for 3 hrsplicing, STAT3 is expressed as two isoforms, STAT3
with antibodies against STAT1 (Santa Cruz Biotechnology), phos-
and STAT3 (Schaefer et al., 1997), both of which were pho-STAT1 (Cell Signaling), STAT3 (C-20, Santa Cruz), phospho-
functionally ablated by our targeting strategy. STAT3 STAT3 (Cell Signaling), STAT5 (Santa Cruz), phospho-STAT5 (Trans-
lacks a transactivation domain and antagonizes the ac- duction Laboratories), RelB and PU.1 (all Santa Cruz), and -actin
(Sigma). Protein bands were visualized using secondary horseradishtivity of STAT3. Therefore, to what extent these two
Role of STAT3/Flt3L in Dendritic Cells
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peroxidase (HRP)-conjugated antibodies and the ECL detection sys- Feldman, G.M., Rosenthal, L.A., Liu, X., Hayes, M.P., Wynshaw-
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(1997). STAT5A-deficient mice demonstrate a defect in granulocyte-
macrophage colony-stimulating factor-induced proliferation andStatistical Analysis
p values were calculated with a nonpaired Student’s t test. gene expression. Blood 90, 1768–1776.
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